JPH02212460A - Novel substituted and compound - Google Patents
Novel substituted and compoundInfo
- Publication number
- JPH02212460A JPH02212460A JP3324989A JP3324989A JPH02212460A JP H02212460 A JPH02212460 A JP H02212460A JP 3324989 A JP3324989 A JP 3324989A JP 3324989 A JP3324989 A JP 3324989A JP H02212460 A JPH02212460 A JP H02212460A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- bis
- pyridine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 34
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 125000002252 acyl group Chemical group 0.000 claims abstract description 7
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 7
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- -1 amide compound Chemical class 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 150000001342 alkaline earth metals Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 abstract description 21
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 17
- 238000006243 chemical reaction Methods 0.000 abstract description 16
- 239000002904 solvent Substances 0.000 abstract description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 239000002585 base Substances 0.000 abstract description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 abstract description 3
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 3
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 2
- 208000024780 Urticaria Diseases 0.000 abstract description 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000000921 elemental analysis Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 230000000704 physical effect Effects 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 6
- 230000003266 anti-allergic effect Effects 0.000 description 5
- GJNGXPDXRVXSEH-UHFFFAOYSA-N 4-chlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C=C1 GJNGXPDXRVXSEH-UHFFFAOYSA-N 0.000 description 4
- KZFCUYQEGLVKTM-UHFFFAOYSA-N (2-chloro-2-oxoethyl) propanoate Chemical compound CCC(=O)OCC(Cl)=O KZFCUYQEGLVKTM-UHFFFAOYSA-N 0.000 description 3
- BLNVISNJTIRAHF-UHFFFAOYSA-N 4-chlorobenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1 BLNVISNJTIRAHF-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NHWQMJMIYICNBP-UHFFFAOYSA-N 2-chlorobenzonitrile Chemical compound ClC1=CC=CC=C1C#N NHWQMJMIYICNBP-UHFFFAOYSA-N 0.000 description 2
- PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical compound ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- WSZPYJYHSUKXKF-UHFFFAOYSA-N (2-amino-2-oxoethyl) propanoate Chemical compound CCC(=O)OCC(N)=O WSZPYJYHSUKXKF-UHFFFAOYSA-N 0.000 description 1
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- YLPNLUJHBADYPT-UHFFFAOYSA-N 2,3-diaminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1N YLPNLUJHBADYPT-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- ZKBYBYGNWFJHGD-UHFFFAOYSA-N 3,5-diamino-4-chlorobenzamide Chemical compound NC(=O)C1=CC(N)=C(Cl)C(N)=C1 ZKBYBYGNWFJHGD-UHFFFAOYSA-N 0.000 description 1
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- CJMBDLFFCOOSEU-UHFFFAOYSA-N [2-[2-chloro-5-cyano-3-[(2-propanoyloxyacetyl)amino]anilino]-2-oxoethyl] propanoate Chemical compound CCC(=O)OCC(=O)NC1=CC(C#N)=CC(NC(=O)COC(=O)CC)=C1Cl CJMBDLFFCOOSEU-UHFFFAOYSA-N 0.000 description 1
- WKOWPOWYYYUWOG-UHFFFAOYSA-N [2-[5-carbamoyl-2-chloro-3-[(2-propanoyloxyacetyl)amino]anilino]-2-oxoethyl] propanoate Chemical compound C(CC)(=O)OCC(=O)NC=1C=C(C(=O)N)C=C(C=1Cl)NC(COC(CC)=O)=O WKOWPOWYYYUWOG-UHFFFAOYSA-N 0.000 description 1
- OTOZRMSGZQUULI-UHFFFAOYSA-N [2-oxo-2-[3-[(2-propanoyloxyacetyl)amino]anilino]ethyl] propanoate Chemical compound C(CC)(=O)OCC(=O)NC1=CC(=CC=C1)NC(COC(CC)=O)=O OTOZRMSGZQUULI-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- BNTAPIYHWPPFBW-UHFFFAOYSA-N ethyl 2-[2-chloro-5-cyano-3-[(2-ethoxy-2-oxoacetyl)amino]anilino]-2-oxoacetate Chemical group CCOC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(=O)OCC)=C1Cl BNTAPIYHWPPFBW-UHFFFAOYSA-N 0.000 description 1
- IDLVQOMJOKNXSL-UHFFFAOYSA-N ethyl 3,5-diaminobenzoate Chemical compound CCOC(=O)C1=CC(N)=CC(N)=C1 IDLVQOMJOKNXSL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 125000000346 malonyl group Chemical group C(CC(=O)*)(=O)* 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000003452 oxalyl group Chemical group *C(=O)C(*)=O 0.000 description 1
- QULYNCCPRWKEMF-UHFFFAOYSA-N parachlorobenzotrifluoride Chemical compound FC(F)(F)C1=CC=C(Cl)C=C1 QULYNCCPRWKEMF-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は優れた抗アレルギー作用を有し、抗アレルギー
剤として有用な新規置換アミド化合物に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to a novel substituted amide compound that has excellent antiallergic activity and is useful as an antiallergic agent.
(従来の技術)
従来より各種アレルギー症状の予防、治療剤の研究や開
発が行われており、多(の化合物が報告されている。抗
アレルギー作用を有するアミド化合物としては、例えば
ザ・ジャーナル・オフ・アレルギー・アンド・クリニカ
ル・イムノロジー(TI+e Journal of
Allergy and C11nical Immu
n−ology) 、57巻(階5 ) 、396頁(
1976年)にトラニラスト[N−3,4,(ジメトキ
シシンナモイル)アントラニル酸]が、またエージエン
ツ・アンド・アクションズ(Agents and A
ctions) 、1巻、235頁(1975年)にロ
ドキサマイドエチル[N、N’−(2−クロロ−5−シ
アノ−m−ファニレン)ジオキサミン酸ジエチルエステ
ル]が記載されている。(Prior Art) Research and development of preventive and therapeutic agents for various allergic symptoms has been carried out, and many compounds have been reported. As amide compounds with antiallergic effects, for example, The Journal Off Allergy and Clinical Immunology (TI+e Journal of
Allergy and C11nical Immu
n-ology), volume 57 (floor 5), page 396 (
1976), tranilast [N-3,4, (dimethoxycinnamoyl)anthranilic acid] was introduced by Agents and Actions.
cations), Vol. 1, p. 235 (1975), lodoxamide ethyl [N,N'-(2-chloro-5-cyano-m-phanylene)dioxamic acid diethyl ester] is described.
(発明が解決しようとする問題点)
従来の抗アレルギー剤は各種アレルギー症状、特に気管
支喘息の治療に十分な効果を示しているとは言い難い。(Problems to be Solved by the Invention) Conventional anti-allergic agents cannot be said to be sufficiently effective in treating various allergic symptoms, especially bronchial asthma.
(問題を解決するための手段)
本発明者らはアレルギー症状に対して優れた抗アレルギ
ー作用を示す薬物を得るべく種々の化合物を合成し、そ
の薬理作用を検討した結果、特定のアミド化合物が抗ア
レルギー活性に優れていることを知り、本発明を完成す
るに至った。(Means for Solving the Problem) The present inventors synthesized various compounds in order to obtain drugs that exhibit excellent antiallergic effects against allergic symptoms, and as a result of examining their pharmacological effects, it was found that certain amide compounds We found that it has excellent anti-allergic activity and completed the present invention.
すなわち、本発明の化合物は式:
1式中、R1は炭素数3−10個のアシル基またはアリ
ール基、R1はシアノ基、トリフルオロメチル基、アミ
ノカルボニル基または−GOOR’ (R’は水素原子
、低級アルキル基、アルカリ金属原子またはアルカリ土
類金属原子)で示される基、Rsは水素原子またはハロ
ゲン原子]で示される新規置換アミド化合物である。That is, the compound of the present invention has the formula: 1 where R1 is an acyl group or aryl group having 3 to 10 carbon atoms, R1 is a cyano group, a trifluoromethyl group, an aminocarbonyl group, or -GOOR'(R' is hydrogen Rs is a hydrogen atom or a halogen atom].
本発明の式(1)の化合物においてR1における炭素数
3−10個のアシル基としてはプロピオニル基、ブチリ
ル基、イソブチリル基、バレリル基、イソバレリル基、
ピバロイル基、ヘキサノイル基、ヘプタノイル基、オク
タノイル基、ノナノイル基、デカノイル基、シクロペン
チルカルボニル基、シクロへキシルカルボニル基、オキ
サリル基、マロニル基、スクシニル基、ベンゾイル基ま
たは置換ベンゾイル基などがあり、好ましくはプロピオ
ニル基、ブチリル基、イソブチリル基、ベンゾイル基お
よびオルト−アセトキシベンゾイル基などが挙げられる
。In the compound of formula (1) of the present invention, the acyl group having 3 to 10 carbon atoms in R1 includes a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an isovaleryl group,
Examples include pivaloyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, cyclopentylcarbonyl group, cyclohexylcarbonyl group, oxalyl group, malonyl group, succinyl group, benzoyl group or substituted benzoyl group, preferably propionyl group. group, butyryl group, isobutyryl group, benzoyl group, and ortho-acetoxybenzoyl group.
R”Lよシアノ基、トリフルオロメチル基、アミノカル
ボニル基または−COOR’ (R’は水素原子、低級
アルキル基、アルカリ金属原子またはアルカリ土類金属
原子)で示される基である。R''L is a cyano group, a trifluoromethyl group, an aminocarbonyl group, or a group represented by -COOR'(R' is a hydrogen atom, a lower alkyl group, an alkali metal atom or an alkaline earth metal atom).
R3は水素原子またはハロゲン原子である。R″のハロ
ゲン原子としてはフッ素原子、塩素原子、臭素原子また
はヨウ素原子があり、好ましくは塩素原子が挙げられる
。R3 is a hydrogen atom or a halogen atom. Examples of the halogen atom for R'' include a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, and preferably a chlorine atom.
R4における低級アルキル基としては炭素数1−6個の
アルキル基、例えばメチル基およびエチル基など、アル
カリ金属原子としてはナトリウムおよびカリウムなどが
、アルカリ土類金属原子としてはマグネシウムおよびカ
ルシウムなどが挙げられる。Examples of the lower alkyl group in R4 include alkyl groups having 1 to 6 carbon atoms, such as methyl and ethyl groups, examples of the alkali metal atoms include sodium and potassium, and examples of the alkaline earth metal atoms include magnesium and calcium. .
本発明の化合物は式(n)
9!
ピ4
1式中、R1はジアド基、トリフルオロメチル基、アミ
ノカルボニル基または−COOR’ (R’ ハ水素原
子、低級アルキル基、アルカリ金属原子またはアルカリ
土類金属原子)で示される5 、 Rsは水素原子およ
びハロゲン原子]で示されるジアミノ化合物を式(■)
:
υ
1式中、R1は炭素数3−1O個のアシル基またはアリ
ール基]で示される酸塩化物と反応させることにより製
造される。The compound of the present invention has the formula (n) 9! 4, where R1 is a diado group, a trifluoromethyl group, an aminocarbonyl group, or -COOR'(R' is a hydrogen atom, a lower alkyl group, an alkali metal atom or an alkaline earth metal atom), Rs is a hydrogen atom and a halogen atom] A diamino compound represented by the formula (■)
: υ In formula 1, R1 is an acyl group or aryl group having 3 to 10 carbon atoms.
反応はピリジン、クロロホルム、ジクロロメタン、N、
N−ジメチルホルムアミドなどの溶媒中、ピリジン、ト
リエチルアミンなどの塩基の存在下で実施される8反応
は外部からの熱の適用なしに起きるが、反応完結を確実
なものにするため、加熱してもよい。The reaction involves pyridine, chloroform, dichloromethane, N,
The 8 reaction, which is carried out in a solvent such as N-dimethylformamide and in the presence of a base such as pyridine or triethylamine, occurs without the application of external heat, but can be heated to ensure completion of the reaction. good.
反応は5chotten Baus+an法の様にアル
カリ水溶液存在下でも行われる。The reaction is also carried out in the presence of an alkaline aqueous solution like the 5-chotten Baus+an method.
また、本発明の化合物は式(■):
p!
1(’
し式中、R”はシアノ基、トリフルオロメチル基、アミ
ノカルボニル基または−GOOR”(R’は水素原子、
低級アルキル基、アルカリ金属原子またはアルカリ土類
金属原子)で示される基;R3は水素原子またはハロゲ
ン原子]で示される化合物と式(V)
RI’C1(V)
[式中、R1は炭素数3−10個のアシル基]で示され
る酸塩化物または式(■);
(Rlo)ヨ 0 (■)E式中、R
1は炭素数3−1O個のアシル基]で示される酸無水物
とを反応させることによっても製造される。Moreover, the compound of the present invention has the formula (■): p! 1(' In the formula, R" is a cyano group, a trifluoromethyl group, an aminocarbonyl group, or -GOOR"(R' is a hydrogen atom,
lower alkyl group, alkali metal atom or alkaline earth metal atom); R3 is a hydrogen atom or a halogen atom] and a compound represented by the formula (V) RI'C1(V) [wherein R1 is the number of carbon atoms] 3-10 acyl groups] or an acid chloride represented by the formula (■);
1 is also produced by reacting with an acid anhydride represented by an acyl group having 3 to 1 O carbon atoms.
化合物(IV)と酸塩化物(V)の反応はピリジン、ク
ロロホルム、ジクロロメタン、N、N−ジメチルホルム
アミドなどの溶媒中、ピリジン、トリエチルアミンなど
の塩基の存在下で実施される。The reaction between compound (IV) and acid chloride (V) is carried out in a solvent such as pyridine, chloroform, dichloromethane, N,N-dimethylformamide, etc., in the presence of a base such as pyridine, triethylamine, etc.
反応は外部からの熱の適用なしに起きるが、反応完結を
確実なものにするため、加熱してもよい。The reaction occurs without external application of heat, but heating may be used to ensure completion of the reaction.
反応は5choLLen Bauman法の様にアルカ
リ水溶液存在下でも行われる。The reaction is also carried out in the presence of an alkaline aqueous solution like the 5choLLen Bauman method.
化合物(rV)と酸無水物(Vl)との反応はピリジン
、クロロホルムなどの溶媒中または無溶媒中でピリジン
、トリエチルアミンなどの塩基、硫酸などの酸または塩
化亜鉛などの触媒の存在下でおこなわれる0反応は外部
からの熱の適用なしに起きるが、反応完結を確実なもの
にするため、加熱してもよい。The reaction between the compound (rV) and the acid anhydride (Vl) is carried out in a solvent such as pyridine or chloroform or without a solvent in the presence of a base such as pyridine or triethylamine, an acid such as sulfuric acid, or a catalyst such as zinc chloride. The zero reaction occurs without the application of external heat, but heating may be applied to ensure completion of the reaction.
R4が低級アルキル基である式(1)の化合物はエステ
ル交換反応により、酸アルキル基を該アルキル基とは異
なるアルキル基に変換することができる。In the compound of formula (1) in which R4 is a lower alkyl group, the acid alkyl group can be converted into an alkyl group different from the alkyl group by transesterification.
R4が水素原子である式(1)の化合物は標準的方法に
より水素原子をアルカリ金属原子またはアルカリ土類金
属原子に変換することができる。In compounds of formula (1) where R4 is a hydrogen atom, the hydrogen atom can be converted to an alkali metal or alkaline earth metal atom by standard methods.
本発明の化合物としては、3.5−ビス(プロピオニル
オキシアセチルアミノ)−4−クロロベンゾニトリル、
3.5−ビス(イソブチリルオキシアセチルアミノ)−
4−クロロベンゾニトリル、3.5−ビス(ブチリルオ
キシアセチルアミノ)4−クロロベンゾニトリル、3,
5−ビス(プロピオニルオキシアセチルアミノ)−4−
クロロベンゾニリルオリド、3,5−ビス(プロピオニ
ルオキシアセチルアミノ)安息香酸メチル・1/4水和
物、1.3−ビス(プロピオニルオキシアセチルアミノ
)ベンゼン、1.3−ビス(ベンゾイルオキシアセチル
アミノ)ベンゼン・1/4水和物、3,5−ビス(2−
アセトキシベンゾイルアセチルアミノ)−4−クロロベ
ンゾニトリル、3.5−ビス(フェノキシアセチルアミ
ノ)安息香酸エチル、3,5−ビス(プロピオニルオキ
シアセチルアミノ)−4−クロロベンズアミド、3゜5
−ビス(フェノキシアセチルアミノ)−4−クロロベン
ズアミドなどが挙げられる。The compounds of the present invention include 3,5-bis(propionyloxyacetylamino)-4-chlorobenzonitrile,
3.5-bis(isobutyryloxyacetylamino)-
4-chlorobenzonitrile, 3.5-bis(butyryloxyacetylamino)4-chlorobenzonitrile, 3,
5-bis(propionyloxyacetylamino)-4-
Chlorobenzonylylulide, 3,5-bis(propionyloxyacetylamino)methyl benzoate quarter hydrate, 1,3-bis(propionyloxyacetylamino)benzene, 1,3-bis(benzoyloxyacetyl) Amino)benzene quarter hydrate, 3,5-bis(2-
Acetoxybenzoylacetylamino)-4-chlorobenzonitrile, ethyl 3,5-bis(phenoxyacetylamino)benzoate, 3,5-bis(propionyloxyacetylamino)-4-chlorobenzamide, 3゜5
-bis(phenoxyacetylamino)-4-chlorobenzamide and the like.
(発明の効果)
本発明の化合物は即時型アレルギー反応を強力に抑制す
る作用を有するので、即時型アレルギーに分類される気
管支喘息、じん麻疹、アレルギー性鼻炎などの予防およ
び治療に対して有用である。(Effects of the Invention) The compounds of the present invention have the effect of strongly suppressing immediate allergic reactions, and therefore are useful for the prevention and treatment of bronchial asthma, hives, allergic rhinitis, etc., which are classified as immediate allergic reactions. be.
本発明化合物の抗アレルギー作用は以下に述べる試験例
により確認された。The antiallergic effect of the compound of the present invention was confirmed by the test examples described below.
試験例
抗卵白アルブミンラット血清を一1star系ラット(
雄、体重約200 g )の背部正中線の両側に各々0
.1ae宛、2点ずつ計4点に皮肉注射して受動的に感
作した。48時間後、卵白アルブミンおよびエバンスブ
ルー混液IJI!を尾静脈より投与してPCA(受動皮
膚アナフィラキシ−)反応を惹起した。Test Example Anti-ovalbumin rat serum was applied to 11 star rats (
0 on each side of the dorsal midline of a male (approximately 200 g)
.. I passively sensitized the subjects by injecting iron into 4 subjects, 2 each addressed to 1ae. After 48 hours, ovalbumin and Evans blue mixture IJI! was administered through the tail vein to induce a PCA (passive cutaneous anaphylaxis) reaction.
30分後、青染部を切取り、漏出色素量をにaLaya
maらの方法[Mlcrobiol、L++muno1
.+22巻、89頁(197B) ]に従い測定した。After 30 minutes, cut out the blue dyed area and measure the amount of leaked dye.
The method of ma et al. [Mlcrobiol, L++ muno1
.. +22 volume, page 89 (197B)].
pc^反応惹起30分前に被検化合物を6匹のラントに
30■/ kgずつ経口投与した。第1表に本発明のP
CA反応抑制率を示す。The test compound was orally administered to six runts at a dose of 30 μg/kg 30 minutes before the induction of the pc^ reaction. Table 1 shows P of the present invention.
The CA reaction inhibition rate is shown.
第 1 表
本発明の化合物は、経口、非経口または吸引により投与
されるが、経口投与が好ましい、また、使用に際しては
通常の医薬担体を用いて常法により各種製剤形に調整さ
れる0例えば、経口投与用には錠剤、カプセル剤、顆粒
剤、シロップ剤、粉削などが挙げられる。非経口投与用
には静脈内注射のための水溶液、筋肉内注射のための油
状懸濁液などが挙げられる。Table 1 The compounds of the present invention can be administered orally, parenterally, or by inhalation, but oral administration is preferred. For oral administration, tablets, capsules, granules, syrups, powders, etc. may be mentioned. Examples for parenteral administration include aqueous solutions for intravenous injection, oily suspensions for intramuscular injection, and the like.
また、エアゾルスプレー、あるいは乾燥粉末の形で本発
明の化合物と肺および気管支などが直接接触できるよう
にする吸引器によって投与することもできる。It can also be administered by an aerosol spray or by an inhaler which allows direct contact of the compounds of the invention in dry powder form with the lungs, bronchi, etc.
本発明の化合物の1日あたりの全投与量は2−2000
■である。The total daily dose of the compounds of the invention is 2-2000
■It is.
(実施例)
次に実施例をあげて本発明を更に具体的に説明するが、
本発明はこれらに限定されるものでない。(Example) Next, the present invention will be explained in more detail with reference to Examples.
The present invention is not limited to these.
実施例1
3.5−ビス(プロピニルオキシアセチルアミノ)−4
−クロロベンゾニトリルの製造:4−り00−3. 5
−ジアミノベンゾニトリル1.67 gをクロロホルム
8(ldに懸濁し、トリエチルアミン2.77dを加え
、水浴で冷却下、プロピオニルオキシアセチルクロリド
3.0gを滴下した。室温で6時間撹拌した後、水浴で
冷却下、プロピオニルオキシアセチルクロリド0.8g
を滴下した。Example 1 3.5-bis(propynyloxyacetylamino)-4
-Production of chlorobenzonitrile: 4-ri00-3. 5
- 1.67 g of diaminobenzonitrile was suspended in 8 (ld) chloroform, 2.77 d of triethylamine was added, and 3.0 g of propionyloxyacetyl chloride was added dropwise while cooling in a water bath. After stirring at room temperature for 6 hours, the suspension was added with 2.77 d of triethylamine. Under cooling, 0.8 g of propionyloxyacetyl chloride
was dripped.
室温で2時間撹拌した後、トリエチルアミン0.73−
を加え、水浴で冷却下、プロピオニルオキシアセチルク
ロリド0.8gを滴下した。室温で3時間撹拌した後、
ジエチルエーテル40mを加えた。析出した固体を濾取
し、クロロホルム−ジエチルエーテル(1:1)の混合
溶媒、次いで水で洗浄し、エタノールより再結晶して、
次の物理化学的性質を有する表記化合物1.2g得た。After stirring for 2 hours at room temperature, triethylamine 0.73-
was added, and 0.8 g of propionyloxyacetyl chloride was added dropwise while cooling in a water bath. After stirring at room temperature for 3 hours,
40ml of diethyl ether was added. The precipitated solid was collected by filtration, washed with a mixed solvent of chloroform-diethyl ether (1:1), then with water, and recrystallized from ethanol.
1.2 g of the title compound having the following physicochemical properties were obtained.
融点:14L’C以上で徐々に分解。Melting point: Gradually decomposes above 14L'C.
IR(KBr) : v −3410,3270,22
30,1760,1690゜1580、 1530.
1430. 11?0. 890. 850
. 810cm−’NMR(DMSOdi) :δ
−9,93(2H,brs) 、 7.97(2H,s
)、 4.75(4H,s)、 2.43(4L q
)。IR (KBr): v -3410, 3270, 22
30,1760,1690°1580, 1530.
1430. 11?0. 890. 850
.. 810cm-'NMR (DMSOdi): δ
-9,93(2H,brs), 7.97(2H,s
), 4.75 (4H, s), 2.43 (4L q
).
1.09 (6u、 t )
元素分析値
計算値j C,51,59i H,4,58; N、
10.62゜CI、 8.96 (%)
実測値: C,51,62i H,4,64; N、
]、0.53. 。1.09 (6u, t) Elemental analysis value calculation value j C, 51,59i H, 4,58; N,
10.62° CI, 8.96 (%) Actual value: C, 51,62i H, 4,64; N,
], 0.53. .
c3 8.82 (%)
実施例2
3.5−ビス(イソブチリルオキシアセチルアミノ)−
4−クロロベンゾニトリルの製造:35−ビス(ヒドロ
キシアセチルアミノ)4−クロロベンゾニトリル2,8
gをピリジン50adに熔かし、室温で塩化イソブチリ
ル2゜3!Iiを滴下した。室温で2時間撹拌した後、
溶媒を留去し、得られた油状物に水を加えて固化させた
。固体を濾取し、水洗、乾燥の後、エタノールで再結晶
して、次の物理的性質を有する表記化合物2.3gを得
た。c3 8.82 (%) Example 2 3.5-bis(isobutyryloxyacetylamino)-
Production of 4-chlorobenzonitrile: 35-bis(hydroxyacetylamino)4-chlorobenzonitrile 2,8
Dissolve 50ad of pyridine and add 2°3 of isobutyryl chloride at room temperature. Ii was added dropwise. After stirring at room temperature for 2 hours,
The solvent was distilled off, and water was added to the obtained oil to solidify it. The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol to obtain 2.3 g of the title compound having the following physical properties.
融点:140−141”C
IR(にBr) : v −3430,3360,30
05,2960,2260゜1755、1730.15
95.1525.1480.1445.14001.3
05.1255.1195.1155.1060.88
5.765c+a−NMR(DMSOdi) :δ−9
,92(214,br、s) 、 7.99(211,
s) 。Melting point: 140-141"C IR (Br): v -3430,3360,30
05,2960,2260°1755,1730.15
95.1525.1480.1445.14001.3
05.1255.1195.1155.1060.88
5.765c+a-NMR (DMSOdi): δ-9
,92(214,br,s) ,7.99(211,
s).
4.75 (4B、 s ) 、 2.85−2.4
5 (2H) 、 1.14(12Ld)元素分析値
計算値F C,53,84; H,5,23i N、
9.91 (%)実測値F C,53,59; H,5
,29i N、 9.92 (%)実施例3
3.5−ビス(ブチリルオキシアセチルアミン)−4−
クロロベンゾニトリルの製造:
3.5−ビス(ヒドロキシアセチルアミノ)4−クロロ
ベンゾニトリル2.8gをピリジン50altに溶かし
、室温で塩化ブチリル2.3dを1滴下した。4.75 (4B, s), 2.85-2.4
5 (2H), 1.14 (12Ld) Elemental analysis value calculation value FC, 53,84; H, 5,23i N,
9.91 (%) Actual value FC, 53,59; H, 5
,29i N, 9.92 (%) Example 3 3.5-bis(butyryloxyacetylamine)-4-
Production of chlorobenzonitrile: 2.8 g of 3.5-bis(hydroxyacetylamino)4-chlorobenzonitrile was dissolved in 50 alt of pyridine, and 1 drop of 2.3 d of butyryl chloride was added at room temperature.
室温で2時間撹拌した後、溶媒を留去し、得られた油状
物に水を加えて固化させた。固体を濾取し、水洗、乾燥
の後、エタノールで再結晶して、次の物理的性質を有す
る表記化合物2.8gを得た。After stirring at room temperature for 2 hours, the solvent was distilled off, and the resulting oil was solidified by adding water. The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol to obtain 2.8 g of the title compound having the following physical properties.
融点: I43−144°C
IR(KBr) : y =3425.3280.29
80.2950.2880゜2245、1?55.16
85.1580.1535.1435.1260120
5、1160.1120.10?5.965.880.
755cm−’NMR(DMSO−di) :δ−9
,93(211,br、s)、 7.98(2H,s)
、 4.75(4L s)、 2.10(4H,t)
。Melting point: I43-144°C IR (KBr): y = 3425.3280.29
80.2950.2880°2245, 1?55.16
85.1580.1535.1435.1260120
5, 1160.1120.10?5.965.880.
755cm-'NMR (DMSO-di): δ-9
,93(211,br,s), 7.98(2H,s)
, 4.75 (4L s), 2.10 (4H,t)
.
1.60 (4L m ) 、 0.94 (6)1.
t )元素分析値
計算値: C,53,84、H,5,23i N、 9
.91 (%)実測値: C,53,62; H,5,
28i N、 9.88 (%)実施例4
3.5−ビス(プロピオニルオキシアセチルアミノ)−
4−クロロペンゾトリフルオリドの製造3.5−ビス(
ヒドロキシアセチルアミノ)4−クロロベンゾトリフル
オリド1.2gをピリジン30H1に溶かし、室温で塩
化プロピオニル0.7mを滴下した。室温で2時間撹拌
した後、溶媒を留去し、得られた油状物に水を加え固化
させた。固体を濾取し、水洗、乾燥の後、エタノールで
再結晶して、次の物理的性質を有する表記化合物1.O
gを得た。1.60 (4L m), 0.94 (6)1.
t) Calculated elemental analysis values: C, 53, 84, H, 5, 23i N, 9
.. 91 (%) Actual value: C, 53, 62; H, 5,
28i N, 9.88 (%) Example 4 3.5-bis(propionyloxyacetylamino)-
Production of 4-chloropenzotrifluoride 3.5-bis(
1.2 g of 4-chlorobenzotrifluoride (hydroxyacetylamino) was dissolved in pyridine 30H1, and 0.7 m of propionyl chloride was added dropwise at room temperature. After stirring at room temperature for 2 hours, the solvent was distilled off, and water was added to the obtained oil to solidify it. The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol to obtain the title compound with the following physical properties: 1. O
I got g.
融点:116−118°C
IR(KBr) : y =3440.3300.17
60.1705.1610゜1560、1535.15
44.1435.1375.1275.1180゜11
30、980.925.885cm−’NMR(DMS
O−di) :δ−9,92(2B、 br、s)、
7.93(2H,s)、4.76(4H,s)、2.
44(4H,q)1.09 (61(、t )
元素分析値
計算値: C,46,53; H,4,t3; N、
6.38 (%)実測値: C,46,79; H,4
,22; N、 6.38 (%)実施例5
3.5−ビス(プロピオニルオキシアセチルアミノ)安
息香酸メチル・1/4水和物の製造:3.5−ビス(ヒ
ドロキシアセチルアミノ)安息香酸メチル・1/4水和
物2.1gを無水プロピオン酸5+dに懸濁し、濃硫酸
1滴を加え、6時間室温で撹拌した。ジエチルエーテル
20mを加え、析出した固体を濾取し、水洗した。乾燥
の後、固体をエタノールで再結晶し、次の物理的性質を
有する表記化合物3.0gを得た。Melting point: 116-118°C IR (KBr): y = 3440.3300.17
60.1705.1610゜1560, 1535.15
44.1435.1375.1275.1180°11
30, 980.925.885 cm-'NMR (DMS
O-di): δ-9,92 (2B, br, s),
7.93 (2H, s), 4.76 (4H, s), 2.
44 (4H, q) 1.09 (61 (, t) Elemental analysis value calculation value: C, 46, 53; H, 4, t3; N,
6.38 (%) Actual value: C, 46,79; H, 4
, 22; N, 6.38 (%) Example 5 Production of methyl 3.5-bis(propionyloxyacetylamino)benzoate quarter hydrate: 3.5-bis(hydroxyacetylamino)benzoic acid 2.1 g of methyl quarter hydrate was suspended in 5+d propionic anhydride, 1 drop of concentrated sulfuric acid was added, and the mixture was stirred at room temperature for 6 hours. 20 ml of diethyl ether was added, and the precipitated solid was collected by filtration and washed with water. After drying, the solid was recrystallized from ethanol to yield 3.0 g of the title compound with the following physical properties.
融点167−168℃
IR(KBr) : y =3470.3380.30
20.2980.1?40゜1720、1620.15
65.1475.1445.1395.1350゜12
65、1240.1190.1100.1005.88
0.780cmNMR(DMSOdi) :δ−10,
26(2tl、 br、s)、 8.12(LH,t)
、7.91 (2H,d)、4.72(4H,s)。Melting point 167-168℃ IR (KBr): y = 3470.3380.30
20.2980.1?40°1720, 1620.15
65.1475.1445.1395.1350°12
65, 1240.1190.1100.1005.88
0.780cmNMR (DMSOdi): δ-10,
26 (2tl, br, s), 8.12 (LH, t)
, 7.91 (2H, d), 4.72 (4H, s).
3.87 (38,s ) 、 2.41
(4H,q) 、 1.06 (6H,書、
)元素分析値
計算値F C,54,20; H,5,68; N、
7.02 (%)実測値: C,54,41; H,5
,47; N、 7.13 C%)実施例6
1.3−ビス(プロピオニルオキシアセチルアミノ)ベ
ンゼンの製造:
1.3−ビス(ヒドロキシアセチルアミノ)ベンゼン2
.2gをピリジン50adに溶かし、塩化プロピオニル
1.9dを滴下した。室温で3時間撹拌した後、溶媒を
留去し、得られた油状物に水を加え固化させた。固体を
濾取し、水洗、乾燥の後、エタノールで再結晶して、次
の物理的性質を有する表記化合物3.0gを得た。3.87 (38,s), 2.41
(4H, q), 1.06 (6H, writing,
) Elemental analysis value calculation value F C, 54, 20; H, 5, 68; N,
7.02 (%) Actual value: C, 54,41; H, 5
, 47; N, 7.13 C%) Example 6 Production of 1.3-bis(propionyloxyacetylamino)benzene: 1.3-bis(hydroxyacetylamino)benzene 2
.. 2 g was dissolved in 50 ad of pyridine, and 1.9 d of propionyl chloride was added dropwise. After stirring at room temperature for 3 hours, the solvent was distilled off, and water was added to the obtained oil to solidify it. The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol to obtain 3.0 g of the title compound having the following physical properties.
融点: 130−132°C
IR(War) : v −3470,3370,33
15,3005,2960゜1750、1?10.16
90.1620.1570.1555.1500゜14
35、1370.1315.1290.1195.11
?5.1095゜870、790.7QOC1−’
N?lR(DMSO−di) : δ−10,01
(2H,br、s)、7.88(1B、 s )、
7.35−7.15 (3H,m)、4.60 (
4Hs)、2.40(4H,q)、1.05(6H,t
)元素分析値
計算値: C,57,14i H,5,99、N、 8
.33 (%)実測値: C,57,04; H,6,
01; N、 8.35 (%)実施例7
1.3−ビス(ベンゾイルオキシアセチルアミノ)ベン
ゼン・1/4水和物の製造:
1.3−ビス(ヒドロキシアセチルアミノ)ベンゼン2
.2gをピリジン50m1に溶かし、塩化ベンゾイル2
.6dを滴下した。室温で10時間撹拌した後、溶媒を
留去し、得られた油状物に水を加え、固化させた。固体
を濾取し、水洗、乾燥の後、エタノールで再結晶して、
次の物理的性質を有する表記化合物4.2gを得た。Melting point: 130-132°C IR (War): v -3470,3370,33
15,3005,2960°1750,1?10.16
90.1620.1570.1555.1500゜14
35, 1370.1315.1290.1195.11
? 5.1095°870,790.7QOC1-' N? lR(DMSO-di): δ-10,01
(2H, br, s), 7.88 (1B, s),
7.35-7.15 (3H, m), 4.60 (
4Hs), 2.40 (4H, q), 1.05 (6H, t
) Calculated elemental analysis values: C, 57, 14i H, 5, 99, N, 8
.. 33 (%) Actual value: C, 57,04; H, 6,
01; N, 8.35 (%) Example 7 Production of 1.3-bis(benzoyloxyacetylamino)benzene quarter hydrate: 1.3-bis(hydroxyacetylamino)benzene 2
.. Dissolve 2g in 50ml of pyridine and add 2g of benzoyl chloride.
.. 6d was added dropwise. After stirring at room temperature for 10 hours, the solvent was distilled off, and water was added to the resulting oil to solidify it. The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol.
4.2 g of the title compound were obtained having the following physical properties.
融点; 193−197°C
IR(KBr) : v =3460.1730.17
05.1680.1615゜1550、1495.14
55.1435.1320.1275゜1230゜11
80、1125. LO75,1025,715C11
−’NMR(DMSOdi) :δ−10,18(2H
,br、s)、 8.227.05 (14B)、4
.89 (4H,s )元素分析値
計算値:C265,97; H、4,73i N 、
6.41 (%)実測値: C,66,09; H,4
,71; N、 6.61 (%)実施例日
3.5−ビス(2−アセトキシベンゾイルアセチルアミ
ノ)−4−クロロベンゾニトリルの製造3.5−ビス(
ヒドロキシアセチルアミノ)−4−クロロベンゾニトリ
ル2.8gをピリジン50aj!に溶かし、室温で塩化
アセチルサリチロイル4.4gを加えた。室温で2時間
撹拌した後、溶媒を留去し、得られた油状物に水を加え
、固化させた。Melting point; 193-197°C IR (KBr): v = 3460.1730.17
05.1680.1615°1550, 1495.14
55.1435.1320.1275゜1230゜11
80, 1125. LO75,1025,715C11
-'NMR (DMSOdi): δ-10,18 (2H
,br,s), 8.227.05 (14B), 4
.. 89 (4H,s) Elemental analysis value calculation value: C265,97; H, 4,73i N,
6.41 (%) Actual value: C, 66,09; H, 4
, 71; N, 6.61 (%) Example day 3. Production of 5-bis(2-acetoxybenzoylacetylamino)-4-chlorobenzonitrile 3.5-bis(
2.8 g of hydroxyacetylamino)-4-chlorobenzonitrile to 50 aj of pyridine! 4.4 g of acetylsalicyloyl chloride was added at room temperature. After stirring at room temperature for 2 hours, the solvent was distilled off, and water was added to the obtained oil to solidify it.
固体を濾取し、水洗、乾燥の後、エタノールで再結晶し
て、次の物理的性質を有する表記化合物2.6gを得た
。The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol to obtain 2.6 g of the title compound having the following physical properties.
融点:166°Cから分解
fR(lfBr) : y −3440,2240,1
770,1740,161015B5 1515.14
90.1455.1435.1375.1295゜!2
55. 1205. 1180. 1!55. 108
5. 1010.915,880゜760.705cm
−’
NMR(DMSOdh): δ −10,08(2L
br、s)、8.25−7゜10(IOH)、5.
00 (411,s)、2.27 (611,s)
元素分析値
計算値: C,57,29i H,3,65; N、
6.91 (%)実測値: C,57,01; H,3
,63、N、 6゜89(%)実施例9
3.5−ビス(フェノキシアセチルアミノ)安息香酸エ
チルの製造:
3.5−ジアミノ安息香酸エチル1,8gをピリジン5
0+dに溶かし、室温で塩化フェノキシアセチル3.0
mを滴下した。室温で2時間撹拌した後、溶媒を留去し
た。水を加え、酢酸エチルで抽出し、有機層を水、飽和
食塩水で洗浄し、無水硫酸ナトリウムで乾燥した。溶媒
を留去し、得られた油状物に少量のエタノールを加え、
固化させた。固体を濾取し、ジエチルエーテルで洗浄し
、乾燥の後エタノールで再結晶して、次の物理的性質を
有する表記化合物2.1gを得た。Melting point: Decomposition from 166°C fR (lfBr): y -3440,2240,1
770,1740,161015B5 1515.14
90.1455.1435.1375.1295°! 2
55. 1205. 1180. 1!55. 108
5. 1010.915,880°760.705cm
-' NMR (DMSOdh): δ -10,08 (2L
br, s), 8.25-7°10 (IOH), 5.
00 (411,s), 2.27 (611,s)
Calculated elemental analysis value: C, 57,29i H, 3,65; N,
6.91 (%) Actual value: C, 57,01; H, 3
,63,N, 6°89 (%) Example 9 Production of ethyl 3.5-bis(phenoxyacetylamino)benzoate: 1.8 g of ethyl 3.5-diaminobenzoate was dissolved in pyridine 5
Phenoxyacetyl chloride 3.0 dissolved in 0+d at room temperature
m was added dropwise. After stirring at room temperature for 2 hours, the solvent was distilled off. Water was added, extracted with ethyl acetate, and the organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The solvent was distilled off, a small amount of ethanol was added to the resulting oil,
Solidified. The solid was collected by filtration, washed with diethyl ether, dried and recrystallized from ethanol to yield 2.1 g of the title compound with the following physical properties.
融点: 140−141 ”C
IR(にBr): v =3480.3440.17
35.1700,1620゜1600.1560.15
05,1470,1445,1380,1345゜13
20.1240. 1185. 1120,1095.
1065. 1035゜890、 855. 7
80. 765. 700c曹 −1N旧?(DM
SOdi) : δ−10,32(2H,br、s
)、8.31(1,o、 t ) 、 8.ol
(2H,d ) 、 7.95−6.75 (
108) 。Melting point: 140-141''C IR (Br): v = 3480.3440.17
35.1700,1620゜1600.1560.15
05,1470,1445,1380,1345゜13
20.1240. 1185. 1120,1095.
1065. 1035°890, 855. 7
80. 765. 700c So -1N old? (DM
SOdi) : δ-10,32(2H,br,s
), 8.31 (1, o, t ), 8. ol
(2H,d), 7.95-6.75 (
108).
4.69(411,s)、4.29(2H,q)、1.
30(3H,t)元素分析値
計算値: C,66,95; H,5,39; N、
6.25 (%)実測値: C,66,97; H,5
,38; N、 6.25 (%)実施例10
3.5−ビス(プロピオニルオキシアセチルアミ/)−
4−クロロベンズアミドの製造:3.5−ビス(ヒドロ
キシアセチルアミノ)4−クロロベンズアミド0.6g
をピリジン15dに溶かし、室温で塩化プロピオニルを
滴下した。室温で2時間撹拌した後、溶媒を留去し、得
られた油状物に水を加えて固化させた。固体を濾取し、
水洗、乾燥の後、エタノールで再結晶して、次の物理的
性質を有する表記化合物0.6gを得た。4.69 (411, s), 4.29 (2H, q), 1.
30 (3H, t) elemental analysis calculated value: C, 66,95; H, 5,39; N,
6.25 (%) Actual value: C, 66,97; H, 5
,38; N, 6.25 (%) Example 10 3.5-bis(propionyloxyacetylamide/)-
Production of 4-chlorobenzamide: 0.6 g of 3.5-bis(hydroxyacetylamino)4-chlorobenzamide
was dissolved in pyridine 15d, and propionyl chloride was added dropwise at room temperature. After stirring at room temperature for 2 hours, the solvent was distilled off, and the resulting oil was solidified by adding water. Filter the solid,
After washing with water and drying, it was recrystallized with ethanol to obtain 0.6 g of the title compound having the following physical properties.
融点:l95−198℃
IR(KBr) : y −3420,3270,29
90,2950,1?45゜1615、1585.14
65.1460.1430.13B0.1290゜12
60、1175.1090.1050.970.890
.840.805.770C1l−’
NMR(DMSOdi) : δ−9,79(2tl
、 br、s)、 7.99(IN、 br、s) 、
7.96 (2H,s ) 、 7.39 (!H,
br、s)4.72(4H,s、) 、 2.4.2(
4L q) 、 1.08 (6H,t)元素分析値
計算値j C,49,34i H,4,87i N、
10.15 (%)実測値: C,49,10、H2S
、00 ; N 、 10.03 (%)実施例11
3.5−ビス(フェノキシアセチルアミノ)4−クロロ
ベンズアミドの製造:
4−クロロ−3,5−ジアミノベンズアミド2.4gを
ピリジン100mに溶かし、室温で塩化フェノキシアセ
チル4.OJdを滴下した。室温で2時間撹拌した後、
溶媒を留去し、得られた油状物に水を加えて固化させた
。固体を濾取し、水洗、乾燥の後、エタノールで再結晶
して、次の物理的性質を有する表記化合物3.6gを得
た。Melting point: 195-198°C IR (KBr): y -3420, 3270, 29
90,2950,1?45°1615,1585.14
65.1460.1430.13B0.1290°12
60, 1175.1090.1050.970.890
.. 840.805.770C1l-' NMR (DMSOdi): δ-9,79 (2tl
, br, s), 7.99(IN, br, s),
7.96 (2H,s), 7.39 (!H,
br,s) 4.72(4H,s,), 2.4.2(
4L q), 1.08 (6H, t) Elemental analysis value calculation value j C, 49,34i H, 4,87i N,
10.15 (%) Actual value: C, 49, 10, H2S
, 00; N, 10.03 (%) Example 11 Production of 3.5-bis(phenoxyacetylamino)4-chlorobenzamide: 2.4 g of 4-chloro-3,5-diaminobenzamide was dissolved in 100 m of pyridine, Phenoxyacetyl chloride at room temperature4. OJd was added dropwise. After stirring at room temperature for 2 hours,
The solvent was distilled off, and water was added to the obtained oil to solidify it. The solid was collected by filtration, washed with water, dried, and then recrystallized with ethanol to obtain 3.6 g of the title compound having the following physical properties.
融点: 250−251°C
IR(XBr) : v −3500,3400,17
15,1705,1690゜1600、1595.15
20.1500.1440.1390.1305゜13
05、1245.1235.1175.1085.10
60.840.755CI ” ’
NMR(DMSO−di): δ −9,89(2H
,br、s)、8.08(2H,s)。Melting point: 250-251°C IR (XBr): v -3500,3400,17
15,1705,1690°1600,1595.15
20.1500.1440.1390.1305゜13
05, 1245.1235.1175.1085.10
60.840.755CI''' NMR (DMSO-di): δ -9,89 (2H
, br, s), 8.08 (2H, s).
7.99 (IH,br、s)、7.60−0.80
(IIH)、4.78(4H,s)元素分析値7.99 (IH, br, s), 7.60-0.80
(IIH), 4.78 (4H, s) elemental analysis value
Claims (1)
リール基;R^2はシアノ基、トリフルオロメチル基、
アミノカルボニル基または−COOR^4(R^4は水
素原子、低級アルキル基、アルカリ金属原子またはアル
カリ土類金属原子)で示される基;R^3は水素原子ま
たはハロゲン原子]で示される新規置換アミド化合物。[Claims] Formula ▲ Numerical formula, chemical formula, table, etc. ▼ (I) [In the formula, R^1 is an acyl group or aryl group having 3 to 10 carbon atoms; R^2 is a cyano group, trifluoro methyl group,
A new substitution represented by an aminocarbonyl group or a group represented by -COOR^4 (R^4 is a hydrogen atom, a lower alkyl group, an alkali metal atom or an alkaline earth metal atom); R^3 is a hydrogen atom or a halogen atom] amide compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1033249A JPH0615517B2 (en) | 1989-02-13 | 1989-02-13 | New substituted amide compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1033249A JPH0615517B2 (en) | 1989-02-13 | 1989-02-13 | New substituted amide compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02212460A true JPH02212460A (en) | 1990-08-23 |
| JPH0615517B2 JPH0615517B2 (en) | 1994-03-02 |
Family
ID=12381216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1033249A Expired - Fee Related JPH0615517B2 (en) | 1989-02-13 | 1989-02-13 | New substituted amide compound |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0615517B2 (en) |
-
1989
- 1989-02-13 JP JP1033249A patent/JPH0615517B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0615517B2 (en) | 1994-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4634037B2 (en) | Xanthine oxidase inhibitor | |
| JPH0523267B2 (en) | ||
| WO2011113369A1 (en) | Preparation methods of methyl-d3-amine and salts thereof | |
| CN111875594A (en) | Indazole heterocycles having phosphodiesterase 4B inhibitory activity | |
| DE3419009A1 (en) | NEW SUBSTITUTED TO (4-AMINOPHENYL) SULPHONES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS | |
| CN107573264A (en) | A kind of preparation technology of the sulfonic acid chloride of 3 cyano group, 5 methoxybenzene 1 | |
| JP2005511689A (en) | Novel specificity inhibitor compound of phospholipase A2 secreted from group II human non-pancreas | |
| LU85999A1 (en) | NEW ISOINDOLINYLALCOYLPIPERAZINES | |
| DE19712960A1 (en) | Benzyloxy-substituted, fused N-heterocycles, processes for their preparation and their use as bradykinin receptor antagonists | |
| CN111892526A (en) | A kind of new preparation method of brivaracetam | |
| JPH03151378A (en) | Benzocycloalkylaminopyridine amines and related compounds | |
| CN106146413A (en) | 2,4-(1H, 3H)-quinazolinedione derivatives and preparation method and use thereof | |
| US4912135A (en) | Amide compounds | |
| JPH02286677A (en) | Tetrazole-substituted piperazine compound and pharmaceutical preparation containing said compound | |
| JPH02300178A (en) | New benzothiazole derivative | |
| TW200913995A (en) | Process for the preparation of benzimidazol thienylamine compounds and derivatives thereof useful as sodium/proton exchanger type 3 inhibitors | |
| JPH0615517B2 (en) | New substituted amide compound | |
| JPH02311451A (en) | Novel benzonitrile derivative | |
| CN104418805B (en) | Dabigatran etexilate intermediate as well as preparation method and application thereof | |
| CN111848527A (en) | A kind of 4-chloro-2-(2-fluoro-4-methoxyphenyl)-6-methoxyquinazoline and its synthetic method | |
| JPH0660145B2 (en) | New substituted acetamide compound | |
| JPH02311450A (en) | Novel benzonitrile derivative | |
| JP5536771B2 (en) | Compound having serotonergic activity, process for producing the same and pharmaceutical composition containing the same | |
| ES2296806T3 (en) | NEW DERIVATIVES OF CIANORIL (OR CIANOHETEROARIL) -CARBONIL-PIPERAZINI L-PIRIMIDINAS, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS. | |
| JPH0581589B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |